New hope for men with Hard-to-Treat prostate cancer
Disease control
Completed
This study tested a new drug called ARN-509 in 127 men with advanced prostate cancer that had stopped responding to standard hormone therapy. The goal was to find a safe dose and see if the drug could lower PSA levels, a marker of cancer activity. The study had two phases: first …
Phase: PHASE1, PHASE2 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 05:33 UTC